An interventional study of Component resolved diagnosis and Standard diagnosis in Asthma and Rhinitis, Allergic, sponsored by Universidade do Porto. Recruiting at 1 site in Portugal. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by Universidade do Porto · Not applicable, Interventional, and Diagnostic
Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and/or pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is supported by large systematic reviews and is recommended as a cornerstone treatment option in allergic disease. Molecular based allergy diagnosis has greatly evolved and the knowledge of molecular allergen sensitization pattern has been used to better define the allergen extract composition of AIT. However, uncertainty remains if this strategy is related to an increase of efficacy. Regulation of allergen extracts for allergen immunotherapy are currently underway in Europe, but there is still lack of standardization of relevant allergens and important differences are seen between allergenic contents.
Therefore, we aim to evaluate, in a real-life setting, the impact of using molecular-based diagnosis versus standard diagnostic tools in the efficacy of aeroallergen immunotherapy, using a pragmatic randomized controlled trial design and also to address the impact of the discrepancy between individual aeroallergen sensitization profiles and the major allergen molecular content of aeroallergen immunotherapy.
Exclusion Criteria:
Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
Diagnostic Test: Standard diagnosis
Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.
Diagnostic Test: Component resolved diagnosis
Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
Change of combined symptom and medication score (CSMS) at 52 weeks
Differences, in the mean change at 52 weeks, of CSMS between groups that were treated with AIT in the component resolved diagnosis versus standard diagnosis groups. CSMS is the sum of the daily symptom score (dSS, score 0 to 3) plus daily medication score (dMS; score 0 to 6)
Time frame: 0 to 52 weeks
Change of combined symptom and medication score (CSMS) at 24 weeks
Difference, in the mean change at 24 weeks, of CSMS between groups were treated with AIT in the component resolved diagnosis versus standard diagnosis groups.
Time frame: 0 to 24 weeks
Change of rhinitis symptoms using visual analogue scale at 52 weeks
Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale. This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.
Time frame: 0 to 52 weeks
Change of rhinitis symptoms using visual analogue scale at 24 weeks
Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale. This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.
Time frame: 0 to 24 weeks
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 52 weeks
Differences between groups (control vs intervention) in the mean change at 52 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks. The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference
Time frame: 0 to 52 weeks
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 24 weeks
Differences between groups (control vs intervention) in the mean change at 24 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks. The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference.
Time frame: 0 to 24 weeks
Change in Asthma Control Test (ACT) at 52 weeks
Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks. ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
Time frame: 0 to 52 weeks
Change in Asthma Control Test (ACT) at 24 weeks
Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks. ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
Time frame: 0 to 24 weeks
Change in quality of life related with rhinitis and asthma at 52 weeks
Difference between groups regarding self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 52 weeks. A change greater than 0.5 will be considered a critically clinically significant difference
Time frame: 0 to 52 weeks
Change in quality of life related with rhinitis and asthma at 24 weeks
Differences between groups regarding the self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 24 weeks. A change greater than 0.5 will be considered a critically clinically significant difference
Time frame: 0 to 24 weeks
Change in ESPIA score- patient reported opinion allergen immunotherapy at 52 weeks
Differences between intervention and control groups in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 52 weeks
Time frame: 0 to 52 weeks
Change in ESPIA score- patient reported opinion allergen immunotherapy at 24 weeks
Differences in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 24 weeks
Time frame: 0 to 24 weeks
Change in the cost impact between groups
Direct and indirect healthcare related costs will be assessed in each of the groups before and after treatment and compared
Time frame: 0 and 52 weeks
Plan to share: No — All data
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade do Porto